EXEL - Exelixis Inc. (EXEL) Q1 2024 Earnings Call Transcript
2024-04-30 21:27:02 ET
Exelixis, Inc. (EXEL)
Q1 2024 Earnings Conference Call
April 30, 2024, 5:00 PM ET
Company Participants
Varant Shirvanian - Director of Investor Relations
Michael Morrissey - President and Chief Executive Officer
Christopher Senner - Executive Vice President and Chief Financial Officer
P.J. Haley - Executive Vice President, Commercial
Amy Peterson - Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
Dana Aftab - Executive Vice President, Discovery and Translational Research and Chief Scientific Officer
Conference Call Participants
Joseph Catanzaro - Piper Sandler
Jason Gerberry - Bank of America
Michael Schmidt - Guggenheim Partners
Gregory Renza - RBC Capital Markets
Joyce Zhou - TD Cowen
Andy Hsieh - William Blair
Jay Olson - Oppenheimer
Chris Shibutani - Goldman Sachs
Derek Archila - Wells Fargo
Silvan Tuerkcan - Citizens JMP
David Lebowitz - Citi
Jeffrey Hung - Morgan Stanley
Lukas Shumway - BMO Capital Markets
Peter Lawson - Barclays
Presentation
Operator
Good day, ladies and gentlemen, and welcome to Exelixis First Quarter 2024 Financial Results Conference Call. My name is Towanda and I will be your operator today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today Mr. Varant Shirvanian, Director of Investor Relations. Please proceed.
Varant Shirvanian
Thank you, Tawanda. Thank you all for joining us for the Exelixis First Quarter 2024 Financial Results Conference Call. Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; P.J. Haley, our Executive Vice President of Commercial; Amy Peterson, our Chief Medical Officer; and Dana Aftab, our Chief Scientific Officer who together will review our progress for the first quarter 2024 ended March 31st, 2024.
During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles. Please refer to today's press release which is posted on our website for an explanation of our reasons for using such non-GAAP measures, as well as tables deriving these measures from our GAAP results.
During the course of this presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial and strategic matters.
Actual events or results could of course differ materially. We refer you to the documents we file from time-to-time with the Securities and Exchange Commission, which under the heading Risk Factors identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including, without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners, and the level of costs associated with discovery, product development, business development and commercialization activities....
Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript